EVE Health Group Limited (ASX:EVE)

Australia · Delayed Price · Currency is AUD

0.0160

0.00 (0.00%)

Sep 25, 2026, 12:09 PM AEST

Market Cap	5.64M -30.6%
Revenue (ttm)	1.15M -33.5%
Net Income	-1.89M
EPS	-0.01
Shares Out	352.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,625
Open	0.0160
Previous Close	0.0160
Day's Range	0.0160 - 0.0160
52-Week Range	0.0140 - 0.0360
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About EVE Health Group

EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also develops Apixaban to treat anticoagulation. The company was formerly kno... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2003

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol EVE

Full Company Profile

Financial Performance

In fiscal year 2026, EVE Health Group's revenue was 1.15 million, a decrease of -33.53% compared to the previous year's 1.73 million. Losses were -1.89 million, 19.7% more than in 2025.

Financial Statements